Register Login

SpringWorks Therapeutics (SWTX)

  • Event
  • Aug. 04, 2022, 10:41 UTC

(10% Negative) SPRINGWORKS THERAPEUTICS, INC. (SWTX) Announces Delay in results Trials for multiple myeloma Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations, Safety Review

Full text
Register to leave comments
  • News bot Oct. 2, 2025, 5:42 p.m.

    📋 SPRINGWORKS THERAPEUTICS, INC. (SWTX) - Clinical Trial Update

    Filing Date: 2022-08-04

    Accepted: 2022-08-04 06:41:17

    Event Type: Clinical Trial Update

    Event Details:

    SpringWorks Therapeutics (SWTX) Announces Clinical Trial Update SpringWorks Therapeutics (SWTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: results, Initiate
    • Diseases/Conditions: multiple myeloma
    • Clinical Stage: Phase 2 Trial, Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: Cohort Expansion Studies
      • Studies with Standard of Care Agents –– Mirdametinib Monotherapy and Combination Therapy Studies in Rare Oncology Indications and Biomarker
      • Defined Solid Tumors Continue to Progress –– BGB
      • 3245 Monotherapy to Advance into Cohort Expansion Studies and Combination Study of BGB
        • planned for the second half of 2022

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: SpringWorks Therapeutics
    • CIK: 0001773427
    • Ticker Symbol: SWTX
    • Period End Date: 2022-08-04
    • Document Type: 8-K

Search

News categories